@article{f1cafd3ca225479f8de562311ec9ac44,
title = "Plasma lipid profiling of tissue-specific insulin resistance in human obesity",
abstract = "Background/Objectives Obesity-associated insulin resistance (IR) may develop in multiple organs, representing different aetiologies towards cardiometabolic diseases. This study aimed to identify distinct plasma lipid profiles in overweight/obese individuals who show muscle-IR and/or liver-IR.Subjects/Methods Baseline data of the European multicenter DiOGenes project were used (n = 640; 401 women, nondiabetic BMI: 27-45 kg/m(2)). Muscle insulin sensitivity index (MIST) and hepatic insulin resistance index (HIRI) were derived from a 5-point oral glucose tolerance test. The 140 plasma lipids were quantified by liquid chromatography-mass spectrometry. Linear mixed models were used to evaluate associations between MISI, HIRI and plasma lipids.Results MISI was comparable between sexes while HJRJ and triacylglycerol (TAG) levels were lower in women than in men. MISI was associated with higher lysophosphatidylcholine (LPC) levels (standardized (std)beta = 0.126; FDR-p = 0.032). Sex interactions were observed for associations between HIRI, TAG and diacylglycerol (DAG) lipid classes. In women, but not in men, HJRJ was associated with higher levels of TAG (44 out of 55 species) and both DAG species (std(3: 0.139-0.313; FDR-p <0.05), a lower odd-chain/even-chain TAG ratio (std beta = -0.182; FDR-p = 0.005) and a lower very-long-chain/long-chain TAG ratio (std beta = -0.156; FDR-p = 0.037).Conclusions In overweight/obese individuals, muscle insulin sensitivity is associated with higher plasma LPC concentrations. Women have less hepatic IR and lower TAG than men. Nevertheless, hepatic IR is associated with higher plasma TAG and DAG concentrations and a lower abundance of odd-chain and very-long-chain TAG in women, but not in men. This suggests a more pronounced worsening of plasma lipid profile in women with the progression of hepatic IR.",
keywords = "SKELETAL-MUSCLE, LIPOPROTEIN METABOLISM, FATTY-ACIDS, PHOSPHOLIPIDS, INTERVENTION, PHENOTYPE, SERUM, INDEX, DIET, MASS",
author = "{van der Kolk}, {Birgitta W.} and Nicole Vogelzangs and Jocken, {Johan W. E.} and Armand Valsesia and Thomas Hankemeier and Arne Astrup and Saris, {Wim H. M.} and Arts, {Ilja C. W.} and {van Greevenbroek}, {Marleen M. J.} and Blaak, {Ellen E.} and {CODAM study}",
note = "Funding Information: Conflict of interest AV is a full-time employee at Nestl{\'e} Institute of Health Sciences SA. WHMS reports having received research support from several food companies such as Nestl{\'e}, DSM, Unilever, Nutrition et Sante and Danone as well as Pharmaceutical companies such as GSK, Novartis and Novo Nordisk; he is an unpaid scientific advisor for the International Life Science Institute, ILSI Europe. AA reports grants and personal fees from Global Dairy Platform, personal fees from McCain Foods, McDonald{\textquoteright}s, Arena Pharmaceuticals Inc., Basic Research, Dutch Beer Knowledge Institute, Netherlands, Gelesis, Novo Nordisk, Denmark, Orexigen Therapeutics Inc., S-Biotek, Denmark, Twinlab and Vivus Inc., grants from Arla Foods, Denmark, Danish Dairy Research Council and Nordea Foundation, Denmark, outside the submitted work, and royalties received for the book first published in Danish as 'Verdens Bedste Kur' (Politiken; Copenhagen, Denmark), and subsequently published in Dutch as 'Het beste dieet ter wereld' (Kosmos Uitgevers; Utrecht/Antwerpen, Netherlands), in Spanish as 'Plan DIOGENES para el control del peso. La dieta per-sonalizada inteligente' (Editorial Evergra f{\'i} cas; L{\'e}on, Spain) and in English as 'World{\textquoteright}s Best Diet' (Penguin, Australia). EEB receives grant support from food industry such as DSM, Danone, Friesland Campina, Avebe and Sensus, partly within the context of public–private consortia and has received funding from pharmaceutical companies like Novartis. She is involved in several task forces/ expert groups related to the International Life Science Institute, ILSI Europe. Funding Information: Funding This study was supported by the European Commission, Food Quality and Safety Priority of the Sixth Framework Program (FP6-2005-513946), through a grant from the Maastricht University Medical Center and Nestl{\'e} Institute of Health Sciences, Lausanne, Switzerland. Publisher Copyright: {\textcopyright} 2018, Springer Nature Limited.",
year = "2019",
month = may,
doi = "10.1038/s41366-018-0189-8",
language = "English",
volume = "43",
pages = "989--998",
journal = "International Journal of Obesity",
issn = "0307-0565",
publisher = "Springer",
number = "5",
}